OliX Pharmaceuticals,Inc (226950.KQ)

OliX Pharmaceuticals,Inc (226950.KQ) — VMCI valuation read

226950.KQ screens at VMCI 34/100, a 16-point gap below the Healthcare sector median (50). For a mid-cap OliX Pharmaceuticals,Inc share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

226950.KQ has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 226950.KQ trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.3x leaves covenant headroom, which sets the rate-cycle exposure for OliX Pharmaceuticals,Inc.

226950.KQ fell 3.9% over the trailing 7 days, with a -16.0% read on a 30-day basis.